CVM

CEL-SCI Corporation (CEL-SCI) - 10-Q Summary

Business Context and Reporting Period

Company: CEL-SCI Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2009
Business Overview: CEL-SCI is a biopharmaceutical company focused on the development of Multikine (for cancer treatment) and L.E.A.P.S. technology. The company has not generated revenue from product sales and relies on financing, licensing agreements, and contract manufacturing services to fund operations. The company operates under a "going concern" opinion, requiring additional capital to continue operations.

Key Financial Metrics (Six Months Ended March 31, 2009)

Material Changes vs. Prior Period

• Net Loss Improvement: Net loss decreased to $(3.85) million for the six months ended March 31, 2009, compared to $(5.05) million in the same period in 2008. This improvement was driven by a significant gain on derivative instruments ($656,243) compared to a loss of $(170,949) in the prior year.
• Revenue: Total revenue increased to $19,643 from $1,530 in the prior year, primarily due to rent income.
• Expenses:
  • R&D: Increased slightly to $2.21 million from $2.07 million, driven by preparation for the Multikine Phase III clinical trial.
  • G&A: Decreased significantly to $2.07 million from $2.75 million, largely due to the absence of large non-recurring stock-based compensation expenses recorded in the prior year.
• Cash Position: Cash and cash equivalents decreased by $57,092 during the period, a significant improvement over the $10.7 million decrease in the prior year.

Outlook, Risks, and Management Commentary

• Liquidity and Capital Resources: The company expects to have sufficient capital to continue operations through March 2010, contingent on the $5 million Equity Line of Credit and potential financing from corporate partnerships. However, there is no assurance that financing will be available.
• Phase III Clinical Trial: The company is preparing for the Phase III clinical trial of Multikine but has delayed the start until firm financial commitments are secured. Two partners have agreed to fund part of the trial.
• Debt Obligations: Holders of the Series K Convertible Notes may require repayment of the entire remaining principal balance ($1.69 million) at any time after August 4, 2009. The company may settle this debt in stock rather than cash.
• Lease Compliance: The company was not in compliance with lease requirements in December 2008 regarding base rent. An amendment was reached to defer rent payments, with the company currently paying half of the basic monthly rent while negotiating further financing.
• Risks: Significant risks include the inability to raise additional capital, the uncertainty of FDA approval for Multikine, and the potential exercise of put options by debt holders or default notices from the landlord.

Key Facts for Investor Verification

• Cash Runway: Verify the company's ability to secure the necessary financing to fund operations through March 2010 and the Phase III clinical trial.
• Debt Settlement: Monitor the status of the Series K Notes and whether holders will demand repayment after August 4, 2009, and the company's ability to settle via stock issuance.
• Lease Status: Confirm the ongoing negotiations with the landlord regarding the manufacturing facility lease and the company's ability to meet future rent obligations.
• Derivative Valuation: Note that a significant portion of the net loss reduction was due to a non-cash gain on derivative instruments ($656,243), which is highly sensitive to stock price fluctuations.
• Going Concern: Acknowledge the "going concern" opinion issued by auditors, indicating substantial doubt about the company's ability to continue as a going concern without additional financing.